Innate Pharma (IPHA) Total Non-Current Liabilities (2017 - 2025)

Innate Pharma (IPHA) has 9 years of Total Non-Current Liabilities data on file, last reported at $55.6 million in Q4 2025.

• For the quarter ending Q4 2025, Total Non-Current Liabilities fell 24.84% year-over-year to $55.6 million; the trailing twelve-month figure through Dec 2025 stood at $55.6 million (down 24.84% YoY), and the FY2025 full-year result was $55.6 million, down 24.84% from the prior year.
• Total Non-Current Liabilities for Q4 2025 stood at $55.6 million, down from $66.1 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $112.7 million in Q2 2023 and bottomed at $55.6 million in Q4 2025.
• The 5-year median for Total Non-Current Liabilities is $91.3 million (2021), against an average of $89.2 million.
• The widest annual swing landed in 2021, when Total Non-Current Liabilities plunged 99.75%; it then rose 16.68% in 2023.
• A 5-year view of Total Non-Current Liabilities shows it stood at $91.7 million in 2021, then grew by 15.48% to $105.9 million in 2022, then slipped by 15.02% to $90.0 million in 2023, then decreased by 17.79% to $74.0 million in 2024, then fell by 24.84% to $55.6 million in 2025.
• The last three Total Non-Current Liabilities figures came in at $55.6 million (Q4 2025), $66.1 million (Q2 2025), and $74.0 million (Q4 2024), per Business Quant data.

Peer Comparison